Taysha Gene Therapies Inc. (NASDAQ: TSHA) announced it will present new preclinical data supporting the design of TSHA-102 for Rett ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE